Suchergebnisse - "Hypoglycemic Agents adverse effects"

Predictive factors of hypoglycemia in type 2 diabetes: a prospective study using machine learning

Autoren: Shabestari, M. Mehrabbeik, A. Barbieri, S. et al.

Quelle: Sci Rep
Scientific Reports, Vol 15, Iss 1, Pp 1-13 (2025)
Scientific reports, vol. 15, no. 1, pp. 18143

Schlagwörter: SHAP, Science, Type 2 diabetes mellitus, Machine learning, Medicine, Humans, Diabetes Mellitus, Type 2/complications, Diabetes Mellitus, Type 2/blood, Diabetes Mellitus, Type 2/drug therapy, Hypoglycemia/etiology, Hypoglycemia/epidemiology, Hypoglycemia/diagnosis, Hypoglycemia/blood, Machine Learning, Female, Male, Middle Aged, Prospective Studies, Risk Factors, Aged, Blood Glucose/analysis, Adult, Hypoglycemic Agents/adverse effects, Hypoglycemic Agents/therapeutic use, Blood Glucose Self-Monitoring, Glycated Hemoglobin/analysis, Insulin/therapeutic use, Insulin/adverse effects, Hypoglycemia prediction, Article

Dateibeschreibung: application/pdf

Zugangs-URL: https://doaj.org/article/bc217115928642bdaace4bc547fe64d1
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_E928AF7544EC5
https://serval.unil.ch/notice/serval:BIB_E928AF7544EC
https://serval.unil.ch/resource/serval:BIB_E928AF7544EC.P001/REF.pdf

Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials

Autoren: Christoph Wanner Hristo Iliev Nathalia Duarte et al.

Quelle: Adv Ther

Schlagwörter: Male, Heart Failure, ddc:610, Middle Aged, Benzhydryl Compounds/therapeutic use [MeSH], Sodium-Glucose Transporter 2 Inhibitors/therapeutic use [MeSH], Aged [MeSH], Diabetes Mellitus, Type 2/drug therapy [MeSH], Randomized Controlled Trials as Topic [MeSH], Hypoglycemic Agents/adverse effects [MeSH], Male [MeSH], Adverse drug event, Hypoglycemic Agents/therapeutic use [MeSH], Glucosides/adverse effects [MeSH], Original Research, SGLT2 inhibitors, Sodium-Glucose Transporter 2 Inhibitors/adverse effects [MeSH], Adverse drug reaction, Female [MeSH], Benzhydryl Compounds/adverse effects [MeSH], Diabetes Mellitus, Type 2/complications [MeSH], Humans [MeSH], Drug safety, Cardiovascular Diseases [MeSH], Heart Failure [MeSH], Middle Aged [MeSH], Renal Insufficiency, Chronic [MeSH], Glucosides/therapeutic use [MeSH], Empagliflozin, Glucosides, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Humans, Hypoglycemic Agents, Female, Benzhydryl Compounds, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Aged, Randomized Controlled Trials as Topic

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38771475
https://repository.publisso.de/resource/frl:6508947
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-398088
https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/39808
https://doi.org/10.1007/s12325-024-02879-w
https://opus.bibliothek.uni-wuerzburg.de/files/39808/12325_2024_Article_2879.pdf

Risk of diabetic retinopathy and diabetic macular oedema with sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database: A real-world data study from a global Federated Database

Autoren: Aikaterini Eleftheriadou David Riley Sizheng S. Zhao et al.

Quelle: Diabetologia
Eleftheriadou, A, Riley, D, Zhao, S S, Austin, P, Hernández, G, Lip, G Y H, Jackson, T L, Wilding, J P H & Alam, U 2024, 'Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database', Diabetologia, vol. 67, no. 7, pp. 1271-1282. https://doi.org/10.1007/s00125-024-06132-5
Eleftheriadou, A, Riley, D, Zhao, S, Austin, P, Hernandez, G, Lip, G Y H, Jackson, T L, Wilding, J P H & Alam, U 2024, 'Risk of Diabetic Retinopathy and Diabetic Macular Oedema with Sodium-Glucose Co-transporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in type 2 Diabetes : A real-world data study from a global Federated Database', Diabetologia.
Eleftheriadou, A, Riley, D, Zhao, S S, Austin, P, Hernández, G, Lip, G Y H, Jackson, T L, Wilding, J P H & Alam, U 2024, 'Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes : a real-world data study from a global federated database', Diabetologia, vol. 67, no. 7, pp. 1271-1282. https://doi.org/10.1007/s00125-024-06132-5

Schlagwörter: Male, Diabetes Mellitus, Type 2/drug therapy, Article, Macular Edema, Hypoglycemic Agents/adverse effects, Microvascular Disease, Diabetes Mellitus, Humans, Hypoglycemic Agents, Insulin, Retinopathy, Glucagon-Like Peptide-1 Receptor Agonists/adverse effects, Sodium-Glucose Transporter 2 Inhibitors, Aged, Retrospective Studies, 2. Zero hunger, Diabetic Retinopathy, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, Macular Edema/drug therapy, Middle Aged, Microvascular disease, 3. Good health, Insulin/adverse effects, Type 2/drug therapy, Clinical Diabetes, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Female, Diabetic Retinopathy/chemically induced, Clinical diabetes

Dateibeschreibung: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38584180
http://www.scopus.com/inward/record.url?scp=85189428328&partnerID=8YFLogxK
https://doi.org/10.1007/s00125-024-06132-5
https://vbn.aau.dk/da/publications/6e3210be-df3a-4c38-8095-c411a9a430b8
https://vbn.aau.dk/ws/files/721108014/Eleftheriadou_et_al._2024_._Risk_of_diabetic_retinopathy_and_diabetic_macular_oedema_with_sodium-glucose_cotransporter_2_inhibitors_and_glucagon-like_peptide_1_receptor_agonists_in_type_2_diabetes_a_real-world_data_study_f.pdf
https://research.manchester.ac.uk/en/publications/a1cfbaf2-d56d-43ea-8487-8e62e730bbe1
https://research.manchester.ac.uk/en/publications/b9b501b2-1980-47e2-a59d-922d3d5a5039
https://doi.org/10.1007/s00125-024-06132-5
https://pure.manchester.ac.uk/ws/files/293928183/171_Diabetologia_Revision_copy.docx
https://research.manchester.ac.uk/en/publications/a1cfbaf2-d56d-43ea-8487-8e62e730bbe1

Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32‐week randomized trial

Autoren: Liv Vernstrøm Søren Gullaksen Steffen S. Sørensen et al.

Quelle: Vernstrøm, L, Gullaksen, S, Sørensen, S S, Funck, K L, Laugesen, E & Poulsen, P L 2024, 'Separate and combined effects of empagliflozin and semaglutide on vascular function : A 32-week randomized trial', Diabetes, Obesity and Metabolism, vol. 26, no. 5, pp. 1624-1635. https://doi.org/10.1111/dom.15464

Schlagwörter: Blood Glucose, Diabetes Mellitus, Type 2/complications, Blood Glucose Self-Monitoring, Benzhydryl Compounds/adverse effects, macrovascular disease, Glucagon-Like Peptides, Pulse Wave Analysis, glucagon-like peptide-1 analogue, sodium–glucose cotransporter 2 inhibitor, Hypoglycemic Agents/adverse effects, 3. Good health, Treatment Outcome, Diabetes Mellitus, Type 2, Double-Blind Method, Glucosides, Creatinine, Albumins, drug mechanism, Humans, Hypoglycemic Agents, continuous glucose monitoring, type 2 diabetes, Benzhydryl Compounds

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38240066
https://pure.au.dk/portal/en/publications/2dd5d1f7-508b-4be5-be82-9aff7f290893
https://pure.au.dk/portal/en/publications/2dd5d1f7-508b-4be5-be82-9aff7f290893
http://www.scopus.com/inward/record.url?scp=85182704727&partnerID=8YFLogxK
https://doi.org/10.1111/dom.15464
https://pure.au.dk/ws/files/434166896/Diabetes_Obesity_Metabolism_-_2024_-_Vernstr_m_-_Separate_and_combined_effects_of_empagliflozin_and_semaglutide_on_vascular.pdf

Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Post‐authorization safety study based on multinational cohorts

Autoren: Cristina Rebordosa Reimar W. Thomsen Arlene K. Tave et al.

Quelle: Rebordosa, C, Thomsen, R W, Tave, A K, Madsen, M, Beachler, D C, Martinez, D, Garcia-Esteban, R, Plana, E, Tormos, A, Farsani, S F, Perez-Gutthann, S & Pladevall-Vila, M 2024, 'Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes : Post-authorization safety study based on multinational cohorts', Diabetes, Obesity and Metabolism, vol. 26, no. 4, pp. 1291-1304. https://doi.org/10.1111/dom.15429

Schlagwörter: Adult, Male, pharmacoepidemiology, Adolescent, Renal Insufficiency, Chronic/complications, empagliflozin, Hypoglycemic Agents/adverse effects, Diabetic Ketoacidosis, Cohort Studies, Glucosides, Acute Kidney Injury/chemically induced, Humans, Hypoglycemic Agents, Dipeptidyl-Peptidase IV Inhibitors/adverse effects, Benzhydryl Compounds, Renal Insufficiency, Chronic, real-world evidence, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Sodium-Glucose Transporter 2 Inhibitors, antidiabetic drug, Dipeptidyl-Peptidase IV Inhibitors, Diabetic Ketoacidosis/chemically induced, Diabetes Mellitus, Type 2/complications, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, Urinary Tract Infections/epidemiology, Acute Kidney Injury, 3. Good health, Diabetes Mellitus, Type 2, Liver, Urinary Tract Infections, Female

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38234181

Use of Analog and Human Insulin in a European Hemodialysis Cohort With Type 2 Diabetes: Associations With Mortality, Hospitalization, MACE, and Hypoglycemia

Autoren: Thomas Ebert Nosheen Sattar Marni Greig et al.

Quelle: American journal of kidney diseases, vol. 83, no. 1, pp. 18-27

Schlagwörter: insulin, Myocardial Infarction, major adverse cardiovascular events, mortality, Hypoglycemia, 3. Good health, Hospitalization, Humans, Diabetes Mellitus, Type 2/complications, Hypoglycemic Agents/adverse effects, Retrospective Studies, Insulin/therapeutic use, Hypoglycemia/chemically induced, Hypoglycemia/epidemiology, Renal Dialysis, Renal Insufficiency/complications, Hemodialysis, type 2 diabetes, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin, Renal Insufficiency

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37657634
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_B10BC32DD44F0
https://serval.unil.ch/resource/serval:BIB_B10BC32DD44F.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_B10BC32DD44F
https://discovery-pp.ucl.ac.uk/id/eprint/10180600/

Metformin treatment is associated with reduced risk of hypoglycaemia, major adverse cardiovascular events, and all-cause mortality in patients with post-pancreatitis diabetes mellitus: a nationwide cohort study

Autoren: Line Davidsen Morten H Jensen Mathias E Cook et al.

Quelle: Davidsen, L, Jensen, M H, Cook, M E, Vestergaard, P, Knop, F K, Drewes, A M & Olesen, S S 2024, 'Metformin Treatment is Associated with Reduced Risk of Hypoglycaemia, Major Adverse Cardiovascular Events, and All-Cause Mortality in Patients with Post-pancreatitis Diabetes Mellitus: A Nationwide Cohort Study', European Journal of Endocrinology, vol. 190, no. 1, pp. 44-53. https://doi.org/10.1093/ejendo/lvad175

Schlagwörter: Adult, treatment, Diabetes Mellitus, Type 2/complications, pancreatitis, Hypoglycemia/chemically induced, Metformin, Hypoglycemia, Hypoglycemic Agents/adverse effects, 3. Good health, Cohort Studies, 03 medical and health sciences, Glucose, 0302 clinical medicine, Diabetes Mellitus, Type 2, Pancreatitis, Cardiovascular Diseases, diabetes mellitus, Pancreatitis/drug therapy, Humans, Hypoglycemic Agents, Cardiovascular Diseases/drug therapy, metformin, Metformin/adverse effects

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38134412
https://vbn.aau.dk/da/publications/12ce4622-1032-49d2-ac04-3868b241e30c
http://www.scopus.com/inward/record.url?scp=85181766284&partnerID=8YFLogxK
https://doi.org/10.1093/ejendo/lvad175
https://vbn.aau.dk/ws/files/626080435/lvad175.pdf

Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

Autoren: Matthias Blüher Julio Rosenstock Josef Hoefler et al.

Quelle: Diabetologia

Schlagwörter: 0301 basic medicine, 0303 health sciences, Glucagon-Like Peptides, 16. Peace & justice, Glucagon, Article, 3. Good health, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Double-Blind Method, Obesity, Double-Blind Method [MeSH], Type 2 diabetes, Glucagon [MeSH], Semaglutide, Humans [MeSH], Treatment Outcome [MeSH], Diabetes Mellitus, Type 2/drug therapy [MeSH], Survodutide, Glucagon-Like Peptides [MeSH], Diabetes Mellitus, Type 2/chemically induced [MeSH], Glucagon-Like Peptide 1 [MeSH], Glucagon-Like Peptide-1 Receptor Agonists [MeSH], Glucagon-like peptide-1, Hypoglycemic Agents/adverse effects [MeSH], Bodyweight loss, Dual incretin agonist, Peptides [MeSH], Pharmacotherapy, Glucagon-Like Peptide 1, Humans, Hypoglycemic Agents, Peptides

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38095657
https://repository.publisso.de/resource/frl:6518895

Disrupted hypothalamic transcriptomics and proteomics in a mouse model of type 2 diabetes exposed to recurrent hypoglycaemia

Autoren: Judit Castillo-Armengol Flavia Marzetta Ana Rodriguez Sanchez-Archidona et al.

Quelle: Diabetologia
Diabetologia, vol. 67, no. 2, pp. 371-391

Schlagwörter: Proteomics, Blood Glucose, insulin, Hypothalamus, neurons, oligodendrocytes, name=Internal Medicine, Article, Mice, RNA, Small Nuclear, Humans, Animals, Insulin, Hypoglycemic Agents, hypothalamus, counterregulation, Amyloid beta-Peptides, Gene Expression Profiling, neurodegeneration, astrocytes, Glucagon, Glucagon/metabolism, Diabetes Mellitus, Type 2/metabolism, Mice, Inbred C57BL, Hypoglycemia/drug therapy, Insulin/metabolism, Hypothalamus/metabolism, Hypoglycemic Agents/adverse effects, RNA, Small Nuclear/metabolism, Blood Glucose/metabolism, Astrocytes, Counterregulation, Hypoglycaemia, Neurodegeneration, Neurons, Oligodendrocytes, RNA-seq, Hypoglycemia, 3. Good health, Diabetes and Metabolism, hypoglycemia, glucagon, Diabetes Mellitus, Type 2, name=Endocrinology

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38017352
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_DAB1C797DF650
https://serval.unil.ch/resource/serval:BIB_DAB1C797DF65.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_DAB1C797DF65

Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?

Autoren: Scheen, André

Quelle: Expert Review of Clinical Pharmacology. 16:1053-1062

Schlagwörter: Cardiotonic Agents, GLP-1 receptor agonist, heart failure, Cardiotonic Agents/pharmacology, gliflozin, Systèmes cardiovasculaire & respiratoire, Sciences de la santé humaine, Glucagon-Like Peptide-1 Receptor, Hypoglycemic Agents/adverse effects, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, metabolism & nutrition, Cardiovascular & respiratory systems, Glucagon-Like Peptide-1 Receptor/agonists, Humans, Hypoglycemic Agents, Atherosclerosis/complications, Human health sciences, Pharmacy, pharmacology & toxicology, Heart Failure, Cardiovascular Diseases/prevention & control/complications, SGLT2 inhibitor, Pharmacie, pharmacologie & toxicologie, Heart Failure/drug therapy, real-world clinical practice, Atherosclerosis, 3. Good health, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Atherosclerotic cardiovascular disease, cardiovascular outcome trial, Diabetes Mellitus, Type 2/complications/drug therapy, Endocrinologie, métabolisme & nutrition

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37919944
https://hdl.handle.net/2268/312538
https://doi.org/10.1080/17512433.2023.2279193

Adverse effects with tirzepatide:a protocol for a systematic review with meta-analysis and Trial Sequential Analysis

Autoren: Sillassen, Christina Dam Bjerregaard Petersen, Johanne Juul Kamp, Caroline Barkholt et al.

Quelle: Sillassen , C D B , Petersen , J J , Kamp , C B , Grand , J , Dominguez , H , Frølich , A , Gæde , P H , Gluud , C , Mathiesen , O & Jakobsen , J C 2025 , ' Adverse effects with tirzepatide : a protocol for a systematic review with meta-analysis and Trial Sequential Analysis ' , BMJ Open , vol. 15 , no. 4 , e094947 . https://doi.org/10.1136/bmjopen-2024-094947

Schlagwörter: Humans, Systematic Reviews as Topic, Meta-Analysis as Topic, Research Design, Diabetes Mellitus, Type 2/drug therapy, Cardiovascular Diseases, Hypoglycemic Agents/adverse effects, Randomized Controlled Trials as Topic, Tirzepatide

Dateibeschreibung: application/pdf

Verfügbarkeit: https://researchprofiles.ku.dk/da/publications/2ad2c6d0-f927-4463-b2ad-d29688c38594
https://doi.org/10.1136/bmjopen-2024-094947
https://curis.ku.dk/ws/files/448382067/Adverse_effects.pdf

The associations of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors as add‐on to metformin with fracture risk in patients with type 2 diabetes mellitus

Autoren: Veerle van Hulten Johanna H. M. Driessen Jakob K. Starup‐Linde et al.

Weitere Verfasser: Veerle van Hulten Johanna H. M. Driessen Jakob K. Starup‐Linde et al.

Quelle: van Hulten, V, Driessen, J H M, Starup-Linde, J K, Al-Mashhadi, Z K, Viggers, R, Klungel, O H, Souverein, P C, Vestergaard, P, Stehouwer, C D A & van den Bergh, J P 2023, 'The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus', Diabetes, Obesity and Metabolism, vol. 25, no. 11, pp. 3235-3247. https://doi.org/10.1111/dom.15220

Schlagwörter: Male, pharmacoepidemiology, Endocrinology, Diabetes and Metabolism, Glucose/therapeutic use, Hypoglycemic Agents/adverse effects, Cohort Studies, Fractures, Bone, Endocrinology, SDG 3 - Good Health and Well-being, Internal Medicine, cohort study, DPP-4 inhibitor, Humans, Hypoglycemic Agents, Dipeptidyl-Peptidase IV Inhibitors/adverse effects, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Sodium-Glucose Transporter 2 Inhibitors, Metformin/adverse effects, Retrospective Studies, Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2/complications, Sodium, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, diabetes complications, SGLT2 inhibitor, Metformin, 3. Good health, Glucose, Diabetes Mellitus, Type 2, Fractures, Bone/epidemiology, Female, type 2 diabetes, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/metabolism

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37503747
https://pure.au.dk/ws/files/411390158/Diabetes_Obesity_Metabolism_-_2023_-_Hulten_-_The_associations_of_sodium_glucose_cotransporter_2_inhibitors_versus.pdf
https://dspace.library.uu.nl/handle/1874/432841

Evaluation of SGLT-2 inhibitor treatment in type 2 diabetes patients with very high cardiovascular risk

Autoren: Hart, Huberta E Kievits, Olivier Rutten, Frans H et al.

Weitere Verfasser: Hart, Huberta E Kievits, Olivier Rutten, Frans H et al.

Quelle: Hart, H E, Kievits, O, Rutten, F H & Hollander, M H 2023, 'Evaluation of SGLT-2 inhibitor treatment in type 2 diabetes patients with very high cardiovascular risk', Primary care diabetes, vol. 17, no. 2, pp. 190-194. https://doi.org/10.1016/j.pcd.2023.02.001

Schlagwörter: Very high-risk patients, Type 2/diagnosis, Nutrition and Dietetics, Endocrinology, Diabetes and Metabolism, Sodium-Glucose Transporter 2 Inhibitors/adverse effects, Type 2 diabetes, Practice guidelines, 3. Good health, Hypoglycemic Agents/adverse effects, 03 medical and health sciences, Primary care setting, 0302 clinical medicine, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2, Cardiovascular Diseases, Risk Factors, Heart Disease Risk Factors, Diabetes Mellitus, Internal Medicine, Humans, Hypoglycemic Agents, General practice, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases/diagnosis

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36775727
https://research.vumc.nl/en/publications/068dc333-5439-4a77-951d-1476074d7725
https://dspace.library.uu.nl/handle/1874/449508
https://pure.amsterdamumc.nl/en/publications/214178dd-70bf-41c4-a33f-eefab0b19ead
https://doi.org/10.1016/j.pcd.2023.02.001

Nocturnal hypoglycemia is underdiagnosed in older people with insulin‐treated type 2 diabetes: The HYPOAGE observational study

Autoren: Boureau, Anne‐sophie Guyomarc'H-Delasalle, Béatrice Gourdy, Pierre et al.

Weitere Verfasser: Boureau, Anne‐sophie Guyomarc'H-Delasalle, Béatrice Gourdy, Pierre et al.

Quelle: Journal of the American Geriatrics Society. 71:2107-2119

Schlagwörter: Male, Blood Glucose, MESH: Diabetes Mellitus, Type 1, MESH: Blood Glucose / analysis, [SHS.PSY]Humanities and Social Sciences/Psychology, MESH: Blood Glucose Self-Monitoring, [SHS.PSY] Humanities and Social Sciences/Psychology, 80 and over, Type 2* / drug therapy, Humans, Insulin, Hypoglycemic Agents, Prospective Studies, Aged, MESH: Aged, Aged, 80 and over, MESH: Humans, Type 2* / complications, Blood Glucose Self-Monitoring, basal insulin analogues, older patients, MESH: Hypoglycemia* / chemically induced, MESH: Male, MESH: Prospective Studies, Hypoglycemia, 3. Good health, MESH: Insulin / adverse effects, hypoglycemia, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, glycemic control, continuous glucose monitoring, Female, type 2 diabetes, MESH: Hypoglycemia* / epidemiology, MESH: Hypoglycemic Agents / adverse effects, MESH: Female

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36965179
https://nantes-universite.hal.science/hal-04588740v1
https://doi.org/10.1111/jgs.18341
https://nantes-universite.hal.science/hal-04588740v1/document

Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia

Autoren: Julie Maria Bøggild Brøsen Rikke Mette Agesen Peter Lommer Kristensen et al.

Quelle: Brøsen, J M B, Agesen, R M, Kristensen, P L, Alibegovic, A C, Andersen, H U, Beck-Nielsen, H, Gustenhoff, P, Hansen, T K, Hedetoft, C, Jensen, T, Stolberg, C R, Juhl, C B, Lerche, S S, Nørgaard, K, Parving, H-H, Tarnow, L, Thorsteinsson, B & Pedersen-Bjergaard, U 2023, 'Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia', Diabetes, Obesity and Metabolism, vol. 25, no. 6, pp. 1557-1565. https://doi.org/10.1111/dom.15003
Brøsen, J M B, Agesen, R M, Kristensen, P L, Alibegovic, A C, Andersen, H U, Beck-Nielsen, H, Gustenhoff, P, Hansen, T K, Hedetoft, C, Jensen, T, Stolberg, C R, Juhl, C B, Lerche, S S, Nørgaard, K, Parving, H H, Tarnow, L, Thorsteinsson, B & Pedersen-Bjergaard, U 2023, ' Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia ', Diabetes, Obesity and Metabolism, vol. 25, no. 6, pp. 1557-1565 . https://doi.org/10.1111/dom.15003

Schlagwörter: Blood Glucose, type 1 diabetes, insulin analogues, Insulin Glargine, clinical trial, Hypoglycemia/chemically induced, 16. Peace & justice, Insulin Glargine/adverse effects, Hypoglycemia, Hypoglycemic Agents/adverse effects, 3. Good health, 03 medical and health sciences, glycaemic control, Diabetes Mellitus, Type 1, 0302 clinical medicine, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1/drug therapy, Humans, Hypoglycemic Agents, basal insulin, Type 2, hypoglycaemia

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36749303
https://vbn.aau.dk/ws/files/539124056/Diabetes_Obesity_Metabolism_-_2023_-_Br_sen_-_Effect_of_insulin_degludec_versus_insulin_glargine_U100_on_nocturnal.pdf
http://www.scopus.com/inward/record.url?scp=85149986760&partnerID=8YFLogxK
https://vbn.aau.dk/da/publications/c728821a-6d2a-4051-b5bf-3b6ae4088b70
https://doi.org/10.1111/dom.15003
https://pure.au.dk/portal/en/publications/b4c6e12a-3785-45a9-90b6-a8524e8d0df2
https://curis.ku.dk/ws/files/359552667/Diabetes_Obesity_Metabolism_2023_Br_sen_Effect_of_insulin_degludec_versus_insulin_glargine_U100_on_nocturnal.pdf
https://portal.findresearcher.sdu.dk/da/publications/e5243aad-3930-4382-9383-564d8de80ea8
https://doi.org/10.1111/dom.15003
http://www.scopus.com/inward/record.url?scp=85149986760&partnerID=8YFLogxK
https://pure.au.dk/portal/en/publications/b4c6e12a-3785-45a9-90b6-a8524e8d0df2
https://pure.au.dk/ws/files/401315063/Diabetes_Obesity_Metabolism_-_2023_-_Br_sen_-_Effect_of_insulin_degludec_versus_insulin_glargine_U100_on_nocturnal.pdf
https://doi.org/10.1111/dom.15003

Identifying diabetogenic drugs using real world health care databases: A Danish and Australian symmetry analysis: A Danish and Australian symmetry analysis

Autoren: Lars Christian Lund Patricia Hjorslev Jensen Anton Pottegård et al.

Weitere Verfasser: Lars Christian Lund Patricia Hjorslev Jensen Anton Pottegård et al.

Quelle: Lund, L C, Jensen, P H, Pottegård, A, Andersen, M, Pratt, N & Hallas, J 2023, ' Identifying diabetogenic drugs using real world health care databases : A Danish and Australian symmetry analysis ', Diabetes, Obesity and Metabolism, vol. 25, no. 5, pp. 1311-1320 . https://doi.org/10.1111/dom.14982

Schlagwörter: adverse drug reactions, pharmacoepidemiology, Denmark, Australia/epidemiology, Australia, Global Health, Denmark/epidemiology, 3. Good health, Hypoglycemic Agents/adverse effects, 03 medical and health sciences, 0302 clinical medicine, Type 2/drug therapy, Diabetes Mellitus, Type 2, diabetes mellitus, Diabetes Mellitus, Humans, Hypoglycemic Agents, Glucocorticoids

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36683229
https://hdl.handle.net/11541.2/33486
https://curis.ku.dk/ws/files/344973892/Diabetes_Obesity_Metabolism_2023_Lund_Identifying_diabetogenic_drugs_using_real_world_health_care_databases_A_Danish.pdf

Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects

Autoren: Harmanjit Singh Jasbir Singh Ravneet Kaur Bhangu et al.

Quelle: Expert Review of Clinical Pharmacology. 16:49-59

Schlagwörter: safety, Blood Glucose, Diabetes Mellitus, Dipeptidyl-Peptidase IV Inhibitors/adverse effects, Dipeptidyl-Peptidase IV Inhibitors, efficacy, T2dm, teneligliptin, Hypoglycemic Agents/adverse effects, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Diabetes Mellitus, Type 2, DPP-4 inhibitors, Humans, Hypoglycemic Agents, Type 2/drug therapy/epidemiology, Aged

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36567479

Effets des médicaments antidiabétiques sur la stéatopathie métabolique (MAFLD)

Autoren: Scheen, André

Quelle: Revue Médicale Suisse. 19:1498-1502

Schlagwörter: Dipeptidyl-Peptidase IV Inhibitors, Diabetes Mellitus, Type 2/drug therapy, Liraglutide/therapeutic use, Gastroentérologie & hépatologie, Pharmacie, pharmacologie & toxicologie, Sciences de la santé humaine, Hypoglycemic Agents/adverse effects, Non-alcoholic Fatty Liver Disease/drug therapy, Endocrinology, metabolism & nutrition, Hypoglycemic Agents, Humans, 839I73S42A (Liraglutide), Human health sciences, Gastroenterology & hepatology, Pharmacy, pharmacology & toxicology, Endocrinologie, métabolisme & nutrition

Is GFR decline induced by SGLT2 inhibitor of clinical importance?

Autoren: Günes-Altan, Merve Bosch, Agnes Striepe, Kristina et al.

Quelle: Cardiovasc Diabetol
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-12 (2024)

Schlagwörter: Male, Time Factors, Linagliptin, Pulse Wave Analysis, Kidney, 03 medical and health sciences, Vascular Stiffness, 0302 clinical medicine, Glucosides, Diseases of the circulatory (Cardiovascular) system, Humans, Insulin, Diabetic Nephropathies, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors, Aged, PWV, Research, Middle Aged, Metformin, 3. Good health, Treatment Outcome, Diabetes Mellitus, Type 2, RC666-701, GFR decline, Female, Drug Therapy, Combination, Benzhydryl Compounds/therapeutic use [MeSH], Kidney/drug effects [MeSH], Sodium-Glucose Transporter 2 Inhibitors/therapeutic use [MeSH], Aged [MeSH], Diabetic Nephropathies/diagnosis [MeSH], Diabetes Mellitus, Type 2/physiopathology [MeSH], Sodium-Glucose Transporter 2 [MeSH], Diabetes Mellitus, Type 2/drug therapy [MeSH], Metformin/therapeutic use [MeSH], Kidney/physiopathology [MeSH], Hypoglycemic Agents/adverse effects [MeSH], Male [MeSH], Hypoglycemic Agents/therapeutic use [MeSH], Glucosides/adverse effects [MeSH], Clinical Relevance [MeSH], Drug Therapy, Combination [MeSH], SGLT2 inhibitors, Glomerular Filtration Rate/drug effects [MeSH], Sodium-Glucose Transporter 2 Inhibitors/adverse effects [MeSH], Diabetes Mellitus, Type 2/diagnosis [MeSH], Female [MeSH], Linagliptin/therapeutic use [MeSH], Benzhydryl Compounds/adverse effects [MeSH], Biomarkers/blood [MeSH], Humans [MeSH], Insulin [MeSH], Linagliptin/adverse effects [MeSH], Treatment Outcome [MeSH], Middle Aged [MeSH], Time Factors [MeSH], Diabetic Nephropathies/physiopathology [MeSH], Glucosides/therapeutic use [MeSH], Diabetic Nephropathies/drug therapy [MeSH], Pulse Wave Analysis [MeSH], Vascular Stiffness/drug effects [MeSH], Glomerular Filtration Rate

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38811998
https://doaj.org/article/16e1093b68244e548ee9caeec43f6782
https://repository.publisso.de/resource/frl:6506955

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study

Autoren: Hae Jin Kim In Kyung Jeong Kyu Yeon Hur et al.

Weitere Verfasser: Hae Jin Kim In Kyung Jeong Kyu Yeon Hur et al.

Quelle: Diabetes Metab J
Diabetes & Metabolism Journal, Vol 46, Iss 5, Pp 689-700 (2022)

Schlagwörter: Blood Glucose, HDL, Lipoproteins, alogliptin, Uracil / analogs & derivatives, Diseases of the endocrine glands. Clinical endocrinology, Autoimmune Diseases, 03 medical and health sciences, Glycemic control, 0302 clinical medicine, Drug Therapy, Piperidines, Diabetes Mellitus, pioglitazone, Humans, Hypoglycemic Agents, glimepiride, Uracil, Alogliptin, Glycated Hemoglobin, Pioglitazone, Type 2, Blood Glucose Self-Monitoring, Glimepiride, Hypoglycemic Agents / adverse effects, Pioglitazone / therapeutic use, RC648-665, Lipids, Metformin, 3. Good health, Metformin* / therapeutic use, Cholesterol, Sulfonylurea Compounds, Treatment Outcome, type 2, diabetes mellitus, type 2, Diabetes Mellitus, Type 2, Combination, glycemic control, Original Article, Drug Therapy, Combination, Lipoproteins, HDL

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/35295073
https://doaj.org/article/e82396ec1d0c4143a0356bf405815c2f